Flavia Borellini
Net worth: 5 M $ as of 31/07/2026
Net worth: 5 M $ as of 31/07/2026
Dr. Flavia Borellini is an Independent Director at Pliant Therapeutics, Inc., an Independent Director at Revolution Medicines, Inc. and an Independent Director at Cantargia AB. She is on the Board of Directors at Pliant Therapeutics, Inc., Revolution Medicines, Inc., Cantargia AB and Kartos Therapeutics, Inc. Dr. Borellini was previously employed as an Independent Director by Viracta Therapeutics, Inc., a Global Head-Hematology Franchise by AstraZeneca PLC, a Chief Executive Officer by Acerta Pharma BV, a Vice President-Program Leadership by Onyx Pharmaceuticals, Inc., and a Member by Roche Group.
She received her doctorate degree from Università degli Studi di Modena e Reggio Emilia.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 18/06/2026 | 26,215 ( 0.01% ) | 5 M $ | 31/07/2026 | |
| 09/07/2026 | 0 ( -.--% ) | - $ | 31/07/2026 |
| Companies | Position | Start |
|---|---|---|
| REVOLUTION MEDICINES, INC. | Director/Board Member | 22/06/2021 |
| CANTARGIA AB | Director/Board Member | 01/10/2020 |
| PLIANT THERAPEUTICS, INC. | Director/Board Member | 09/07/2026 |
Kartos Therapeutics, Inc.
Kartos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical stage biopharmaceutical company that develops novel and targeted therapeutics | Director/Board Member | 01/02/2018 |
| Companies | Position | End |
|---|---|---|
| VIRACTA THERAPEUTICS, INC. | Director/Board Member | 05/02/2025 |
| ASTRAZENECA PLC | Corporate Officer/Principal | 01/01/2020 |
Acerta Pharma BV
Acerta Pharma BV Pharmaceuticals: GenericHealth Technology Develops drugs for oncology and autoimmune diseases | Chief Executive Officer | 01/02/2019 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Corporate Officer/Principal | 01/10/2013 |
Roche Group
Roche Group Real Estate DevelopmentFinance Manages real estate properties | Corporate Officer/Principal | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 10 |
|---|---|
AstraZeneca PLC
AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Health Technology |
Roche Group
Roche Group Real Estate DevelopmentFinance Manages real estate properties | Finance |
Università degli Studi di Modena e Reggio Emilia
Università degli Studi di Modena e Reggio Emilia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cantargia AB
Cantargia AB Pharmaceuticals: MajorHealth Technology Creates and develops antibody therapeutics for the treatment of leukemia | Health Technology |
Acerta Pharma BV
Acerta Pharma BV Pharmaceuticals: GenericHealth Technology Develops drugs for oncology and autoimmune diseases | Health Technology |
Revolution Medicines, Inc.
Revolution Medicines, Inc. Pharmaceuticals: OtherHealth Technology Develops new therapies derived from natural products | Health Technology |
Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc. BiotechnologyHealth Technology Operates as biopharmaceutical company focuses on discovering and developing novel therapies for the treatment of fibrosis | Health Technology |
Kartos Therapeutics, Inc.
Kartos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical stage biopharmaceutical company that develops novel and targeted therapeutics | Health Technology |
Viracta Therapeutics, Inc.
Viracta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for virus-associated cancers | Health Technology |
Select your edition
All financial news and data tailored to specific country editions